Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29876522 | 0.92 | KCNH2 (0.49) | KCNH2GPR119NR1H2NR1H3MAPK8 | |
| SCHEMBL18128549 | 0.92 | KCNH2 (0.49) | KCNH2GPR119NR1H2NR1H3MAPK8 | |
| SCHEMBL24425207 | 0.91 | KCNH2 (0.48) | KCNH2GPR119NR1H2NR1H3MAPK8 | |
| SCHEMBL18164041 | 0.90 | KCNH2 (0.47) | KCNH2GPR119NR1H2NR1H3MAPK8 | |
| SCHEMBL24425212 | 0.89 | KCNH2 (0.48) | KCNH2GPR119NR1H2NR1H3MAPK8 | |
| SCHEMBL24424987 | 0.88 | KCNH2 (0.45) | KCNH2GPR119NR1H2NR1H3MAPK8 | |
| SCHEMBL25384534 | 0.87 | KRAS (0.37) | KCNH2KRASCYP3A4CYP3A5 | |
| SCHEMBL25384291 | 0.87 | KCNH2 (0.44) | KCNH2GPR119NR1H2NR1H3MAPK8 | |
| SCHEMBL31658079 | 0.85 | KCNH2 (0.43) | KCNH2GPR119NR1H2NR1H3MAPK8 | |
| SCHEMBL18128568 | 0.85 | KCNH2 (0.43) | KCNH2GPR119NR1H2NR1H3MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2023-12-21 | — | — | US | disclosed |
| CN-116867779-A | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| CN-114920738-A | KRas inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | KRAS, NRAS, HRAS | KCNH2 4354/4885GPR119 2832/4885NR1H2 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.